Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Johnson and Johnson
Dow
Merck
Express Scripts

Last Updated: November 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,358,366

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,358,366 protect, and when does it expire?

Patent 7,358,366 protects AVANDARYL and AVANDIA and is included in two NDAs.

Protection for AVANDARYL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-six countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 7,358,366
Title:Thiazolidinedione derivative and its use as antidiabetic
Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione- , maleic acid salt (the "Polymorph") characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm.sup.-1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm.sup.-1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
Inventor(s): Blackler; Paul David James (Cadiz, ES), Giles; Robert Gordon (Tonbridge, GB), Moore; Stephen (Tonbridge, GB), Sasse; Michael John (Tonbridge, GB)
Assignee: SmithKline Beecham p.l.c. (Brentford, Middlesex, GB)
Application Number:11/458,471
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,358,366

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sb Pharmco AVANDARYL glimepiride; rosiglitazone maleate TABLET;ORAL 021700-001 Nov 23, 2005 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Sb Pharmco AVANDARYL glimepiride; rosiglitazone maleate TABLET;ORAL 021700-002 Nov 23, 2005 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Sb Pharmco AVANDARYL glimepiride; rosiglitazone maleate TABLET;ORAL 021700-004 Mar 30, 2007 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Sb Pharmco AVANDARYL glimepiride; rosiglitazone maleate TABLET;ORAL 021700-003 Nov 23, 2005 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Sb Pharmco AVANDARYL glimepiride; rosiglitazone maleate TABLET;ORAL 021700-005 Mar 30, 2007 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,358,366

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9909471.6Apr 23, 1999
United Kingdom9912195.6May 25, 1999

International Family Members for US Patent 7,358,366

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1607   Start Trial
Argentina 023560   Start Trial
Argentina 023750   Start Trial
Australia 2755102   Start Trial
Australia 4307200   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
McKesson
Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.